Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma
Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma.
Relapsed/Refractory Marginal Zone Lymphoma
DRUG: Orelabrutinib|DRUG: Lenalidomide|DRUG: Rituximab|DRUG: Orelabrutinib Placebo
IRC-assessed PFS, Through study completion, an average of 5 year.
Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma.